In this issue of Clinical Watch, we discuss the FDA guidance on biosimilar interchangeability. We suggest criteria for a new gene therapy that is currently the most expensive drug in the world and review real-world costs associated with psychotropic polypharmacy in patients with cancer. Finally, we review claims data to identify asthma patients being treated with a short-acting beta agonist only.
For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions.
